Crizotinib in ALK+ inflammatory myofibroblastic tumors—Current experience and future perspectives

Publisher： John Wiley & Sons Inc

E-ISSN： 1545-5017|65|4|pbc.26920-pbc.26920

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.65, Iss.4, 2018-04, pp. : n/a-n/a

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Myofibroblastic Inflammatory Tumors of the Bladder

By  

Urologia Internationalis, Vol. 72, Iss. 1, 2004-01 ,pp. : 79-81

Karger

Access to resources Recommend Favorite

FN1: A novel fusion partner of ALK in an inflammatory myofibroblastic tumor

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 5, 2015-05 ,pp. : 909-911

John Wiley & Sons Inc

Access to resources Recommend Favorite

Experience in Integrating ALK Testing and Crizotinib into the Routine Treatment of Patients with Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 36, Iss. 6, 2013-04 ,pp. : 342-347

Karger

Access to resources Recommend Favorite

ALK‐Positive Inflammatory Myofibroblastic Tumor of the Nippl

By  

THE BREAST JOURNAL, Vol. 21, Iss. 3, 2015-05 ,pp. : 297-302

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editor in Chief: Response to Eyre et al. “ALK‐positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease”

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 1, 2015-01 ,pp. : 86-87

John Wiley & Sons Inc

Access to resources Recommend Favorite